CD8A and diffuse large B-cell lymphoma: We took advantage of increased FAP expression on DLBCL-FRCs to demonstrate that FAP-targeted immunostimulatory drugs could augment antitumor CD8+ T cell activity induced by glofitamab, utilizing patient LN organotypic cultures.